Clinical Trials Browser

Interventional × Pamidronate × Clear all

NCT04549207 2025-11-28

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Phase 4 Active not recruiting

Breast Neoplasms

NCT00128297 2023-03-28

Pamidronate Administration in Breast Cancer Patients With Bone Metastases

Phase 4 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00004088 2019-07-02

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

Phase 2 Completed

77 enrolled 15 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01907880 2017-07-07

ER11-03

Phase 4 Completed

Breast Neoplasms, Pain

NCT01067989 2015-07-08

Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer

Phase 2 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT02101164 2015-02-18

Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease

Phase 4 Withdrawn

Bone Diseases

NCT02313727 2014-12-10

Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression

Phase 4 Unknown

Spondylitis, Ankylosing

NCT00033332 2014-04-04

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00004906 2013-05-30

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00376883 2007-01-04

Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

Phase 3 Completed

Multiple Myeloma